| 摘要 |
<p>Novel oligopeptides are disclosed for in vivo tumour imaging and therapy. The novel oligopeptides are oligopeptides containing from 4 to 50 peptide units containing as a characteristic triplet therein the amino acid sequence leu-asp-val (LDV), which triplet provides the oligopeptide with a strong in vivo binding affinity for LDV binding sites on tumours and other tissues. For diagnostic purposes the oligopeptides are labelled with a radioactive label, e.g. 125I, whilst for therapeutic purposes the oligopeptides are chemically linked to or conjugated with a cytotoxin, such as the ricin A-chain.</p> |
